Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pemetrexed + cisplatin + cetuximab followed by pemetrexed + cetuximab maintenance in advanced nonsquamous NSCLC
2008-004330-24Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed, cisplatin and cetuximab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started Dec 2008; status: completed.
02
Drugs
pemetrexedcisplatincetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004330-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004330-24.